eMC - trusted, up to date and comprehensive information about medicines
Link to eMC medicine guides website
eMC homepage
Get Medicines Compendium UK app here

Novartis Consumer Health

Novartis Consumer Health UK Ltd, Park View, Riverside Way, Watchmoor Park, Camberley, Surrey, GU15 3YL, UK
Telephone: +44 (0)1276 687300
Fax: +44 (0)1276 687284
Medical Information Direct Line: +44 (0)1403 323 046
Medical Information e-mail: medicalaffairs.uk@novartis.com
Customer Care direct line: +44 (0)1276 687290
Medical Information Fax: +44 (0)1403 324 024

Before you contact this company: often several companies will market medicines with the same active ingredient. Please check that this is the correct company before contacting them. Why?

Summary of Product Characteristics last updated on the eMC: 21/01/2011
SPC Nicotinell mint 2mg medicated chewing gum

When a pharmaceutical company changes an SPC or PIL, a new version is published on the eMC. For each version, we show the dates it was published on the eMC and the reasons for change.

Updated on 21/01/2011 and displayed until Current
Reasons for adding or updating:
  • Change to section 4.1 - Therapeutic indications
  • Change to section 4.2 - Posology and method of administration
  • Change to section 4.6 - Pregnancy and Lactation
  • Change to section 10 date of revision of the text
Date of revision of text on the SPC:   08-Dec-2010
Legal Category:   GSL
Black Triangle (CHM):   NO

Free-text change information supplied by the pharmaceutical company



Section 4.1

Nicotinell gum relieves and/or prevents craving and nicotine withdrawal symptoms associated with tobacco dependence. It is indicated to aid smokers wishing to quit or reduce prior to quitting, to assist smokers who are unwilling or unable to smoke, and as a safer alternative to smoking for smokers and those around them.

 

Nicotinell gum is indicated in pregnant and lactating women making a quit attempt.

 

Nicotinell gum should preferably be used in conjunction with a behavioural support programme.

 

Replaces:

Nicotinell gum is indicated for the relief of nicotine withdrawal symptoms, as an aid to smoking cessation.

 

Concurrent counselling/behavioural support is recommended as it is likely to increase the chances of a successful quit.

 

 

Section 4.2

Deletion of :

Treatment should be discontinued when the dose has been reduced to 1-2 pieces of gum per day. Use of nicotine products like Nicotinell gum beyond 6 months is generally not recommended. Some ex-smokers may need treatment with the gum for longer to avoid returning to smoking. Patients who have been using oral nicotine replacement therapy beyond 9 months are advised to seek additional help and information from health care professionals.

 

 

Section 4.6 –

Pregnancy

Addition of:

Stopping smoking is the single most effective intervention for improving the health of both the pregnant smoker and her baby, and the earlier abstinence is achieved the better.  However, if the mother cannot (or is considered unlikely to) quit without pharmacological support, NRT may be used as the risk to the fetus is lower than that expected with smoking tobacco. Stopping completely is by far the best option but Nicotinell gums may be used in pregnancy as a safer alternative to smoking.   Because of the potential for nicotine-free periods, intermittent dose forms are preferable, but patches may be necessary if there is significant nausea and/or vomiting. If patches are used they should, if possible, be removed at night when the fetus would not normally be exposed to nicotine.

 

Which replaces :

Smoking during pregnancy is associated with risks such as intra-uterine growth retardation, premature birth or still birth.  Stopping smoking is the single most effective intervention for improving the health of the pregnant smoker and her baby.  The earlier abstinence is achieved the better.

Ideally smoking cessation during pregnancy should be achieved without nicotine replacement therapy.  For women unable to quit on their own nicotine replacement therapy  may be recommended to assist a quit attempt.  The risk of using nicotine replacement therapy to the foetus is lower than that expected with tobacco smoking, due to lower maximal plasma concentrations and no additional exposure to polycyclic hydrocarbons and carbon monoxide.

However as nicotine passes to the foetus affecting breathing movements and has a dose-dependant effect on placental/foetal circulation, the decision to use nicotine replacement therapy should be made on a risk-benefit assessment as early on in pregnancy as possible with the aim of discontinuing use after 2-3 months.

Intermittent dose products may be preferable as these usually provide a lower daily dose of nicotine than patches.  However, patches may be preferred if the woman is suffering from nausea during pregnancy.  If patches are used they should be removed before going to bed to avoid exposure overnight when the foetus would not normally be subjected to smoke derived nicotine.

 

 

Lactation

The relatively small amounts of nicotine found in breast milk during NRT use are less hazardous to the infant than second-hand smoke.  Intermittent dose forms would minimize the amount of nicotine in breast milk and permit feeding when levels were at their lowest.  

 

Replaces:

Nicotine from smoking and nicotine replacement therapy is found in breast milk.  However the amounts of nicotine the infant is exposed to is relatively small and less hazardous than the second-hand smoke they would otherwise be exposed to.

Using intermittent dose products, compared to patches, may minimize the amount of nicotine in the breast milk as the time between administrations of nicotine replacement therapy and feeding can be more easily prolonged.

 

 

Section 10

Change of date from 18 June 2008 to 8 December 2010

Updated on 15/08/2008 and displayed until 21/01/2011
Reasons for adding or updating:
  • Change to section 6. 5 - Nature and Contents of Container
  • Change to section 10 date of revision of the text
Date of revision of text on the SPC:   18-Jun-2008
Legal Category:   GSL
Black Triangle (CHM):   NO

Free-text change information supplied by the pharmaceutical company

Addition of new pack sizes to section 6.5.
Updated date of revision of the text in section 10
Updated on 22/05/2008 and displayed until 15/08/2008
Reasons for adding or updating:
  • New SPC for eMC ie an SPC for an existing product, but one that is new for the eMC
Date of revision of text on the SPC:  
Legal Category:   GSL
Black Triangle (CHM):   NO

Free-text change information supplied by the pharmaceutical company

None provided

Active Ingredients/Generics

 
   nicotine polacrilin